Global Neuroprotective Drugs Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

  • receipt Report ID : 152954
  • calendar_today Published On: Apr, 2019
  • file_copy Pages: 116
  • list Pharmaceuticals and Healthcare

Neuroprotective Drugs consist of medications that can be used to protect or preserve the neuronal cells of the brain from degeneration, stress, and injury, which can impair cognitive functions. 

Scope of the Report:

This report focuses on the Neuroprotective Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

The worldwide market for Neuroprotective Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.

Market Segment by Manufacturers, this report covers

Genervon Biopharmaceuticals (Canada)

NeuroVive Pharmaceutical (Sweden)

Ceregene (USA)

BHRPharma (Thailand)

Neuren Pharmaceuticals (Australia)

Allon therapeutics (Canada)

Bionure Inc. (USA)

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Cholinesterase inhibitors

Anti-inflammatory

Others

Market Segment by Applications, can be divided into

Alzheimer's disease

Parkinson's disease

Others

There are 15 Chapters to deeply display the global Neuroprotective Drugs market.

Chapter 1, to describe Neuroprotective Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of Neuroprotective Drugs, with sales, revenue, and price of Neuroprotective Drugs, in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of Neuroprotective Drugs, for each region, from 2013 to 2018;

Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;

Chapter 12, Neuroprotective Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;

Chapter 13, 14 and 15, to describe Neuroprotective Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

Table of Contents

1 Market Overview

1.1 Neuroprotective Drugs Introduction

1.2 Market Analysis by Type

1.2.1 Cholinesterase inhibitors

1.2.2 Anti-inflammatory

1.2.3 Others

1.3 Market Analysis by Applications

1.3.1 Alzheimer's disease

1.3.2 Parkinson's disease

1.3.3 Others

1.4 Market Analysis by Regions

1.4.1 North America (United States, Canada and Mexico)

1.4.1.1 United States Market States and Outlook (2013-2023)

1.4.1.2 Canada Market States and Outlook (2013-2023)

1.4.1.3 Mexico Market States and Outlook (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy)

1.4.2.1 Germany Market States and Outlook (2013-2023)

1.4.2.2 France Market States and Outlook (2013-2023)

1.4.2.3 UK Market States and Outlook (2013-2023)

1.4.2.4 Russia Market States and Outlook (2013-2023)

1.4.2.5 Italy Market States and Outlook (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

1.4.3.1 China Market States and Outlook (2013-2023)

1.4.3.2 Japan Market States and Outlook (2013-2023)

1.4.3.3 Korea Market States and Outlook (2013-2023)

1.4.3.4 India Market States and Outlook (2013-2023)

1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)

1.4.4 South America, Middle East and Africa

1.4.4.1 Brazil Market States and Outlook (2013-2023)

1.4.4.2 Egypt Market States and Outlook (2013-2023)

1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)

1.4.4.4 South Africa Market States and Outlook (2013-2023)

1.4.4.5 Nigeria Market States and Outlook (2013-2023)

1.5 Market Dynamics

1.5.1 Market Opportunities

1.5.2 Market Risk

1.5.3 Market Driving Force

2 Manufacturers Profiles

2.1 Genervon Biopharmaceuticals (Canada)

2.1.1 Business Overview

2.1.2 Neuroprotective Drugs Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 Genervon Biopharmaceuticals (Canada) Neuroprotective Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.2 NeuroVive Pharmaceutical (Sweden)

2.2.1 Business Overview

2.2.2 Neuroprotective Drugs Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 NeuroVive Pharmaceutical (Sweden) Neuroprotective Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.3 Ceregene (USA)

2.3.1 Business Overview

2.3.2 Neuroprotective Drugs Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 Ceregene (USA) Neuroprotective Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.4 BHRPharma (Thailand)

2.4.1 Business Overview

2.4.2 Neuroprotective Drugs Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 BHRPharma (Thailand) Neuroprotective Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.5 Neuren Pharmaceuticals (Australia)

2.5.1 Business Overview

2.5.2 Neuroprotective Drugs Type and Applications

2.5.2.1 Product A

2.5.2.2 Product B

2.5.3 Neuren Pharmaceuticals (Australia) Neuroprotective Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.6 Allon therapeutics (Canada)

2.6.1 Business Overview

2.6.2 Neuroprotective Drugs Type and Applications

2.6.2.1 Product A

2.6.2.2 Product B

2.6.3 Allon therapeutics (Canada) Neuroprotective Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.7 Bionure Inc. (USA)

2.7.1 Business Overview

2.7.2 Neuroprotective Drugs Type and Applications

2.7.2.1 Product A

2.7.2.2 Product B

2.7.3 Bionure Inc. (USA) Neuroprotective Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

3 Global Neuroprotective Drugs Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)

3.1 Global Neuroprotective Drugs Sales and Market Share by Manufacturer (2016-2017)

3.2 Global Neuroprotective Drugs Revenue and Market Share by Manufacturer (2016-2017)

3.3 Market Concentration Rate

3.3.1 Top 3 Neuroprotective Drugs Manufacturer Market Share in 2017

3.3.2 Top 6 Neuroprotective Drugs Manufacturer Market Share in 2017

3.4 Market Competition Trend

4 Global Neuroprotective Drugs Market Analysis by Regions

4.1 Global Neuroprotective Drugs Sales, Revenue and Market Share by Regions

4.1.1 Global Neuroprotective Drugs Sales and Market Share by Regions (2013-2018)

4.1.2 Global Neuroprotective Drugs Revenue and Market Share by Regions (2013-2018)

4.2 North America Neuroprotective Drugs Sales and Growth Rate (2013-2018)

4.3 Europe Neuroprotective Drugs Sales and Growth Rate (2013-2018)

4.4 Asia-Pacific Neuroprotective Drugs Sales and Growth Rate (2013-2018)

4.5 South America Neuroprotective Drugs Sales and Growth Rate (2013-2018)

4.6 Middle East and Africa Neuroprotective Drugs Sales and Growth Rate (2013-2018)

5 North America Neuroprotective Drugs by Countries

5.1 North America Neuroprotective Drugs Sales, Revenue and Market Share by Countries

5.1.1 North America Neuroprotective Drugs Sales and Market Share by Countries (2013-2018)

5.1.2 North America Neuroprotective Drugs Revenue and Market Share by Countries (2013-2018)

5.2 United States Neuroprotective Drugs Sales and Growth Rate (2013-2018)

5.3 Canada Neuroprotective Drugs Sales and Growth Rate (2013-2018)

5.4 Mexico Neuroprotective Drugs Sales and Growth Rate (2013-2018)

6 Europe Neuroprotective Drugs by Countries

6.1 Europe Neuroprotective Drugs Sales, Revenue and Market Share by Countries

6.1.1 Europe Neuroprotective Drugs Sales and Market Share by Countries (2013-2018)

6.1.2 Europe Neuroprotective Drugs Revenue and Market Share by Countries (2013-2018)

6.2 Germany Neuroprotective Drugs Sales and Growth Rate (2013-2018)

6.3 UK Neuroprotective Drugs Sales and Growth Rate (2013-2018)

6.4 France Neuroprotective Drugs Sales and Growth Rate (2013-2018)

6.5 Russia Neuroprotective Drugs Sales and Growth Rate (2013-2018)

6.6 Italy Neuroprotective Drugs Sales and Growth Rate (2013-2018)

7 Asia-Pacific Neuroprotective Drugs by Countries

7.1 Asia-Pacific Neuroprotective Drugs Sales, Revenue and Market Share by Countries

7.1.1 Asia-Pacific Neuroprotective Drugs Sales and Market Share by Countries (2013-2018)

7.1.2 Asia-Pacific Neuroprotective Drugs Revenue and Market Share by Countries (2013-2018)

7.2 China Neuroprotective Drugs Sales and Growth Rate (2013-2018)

7.3 Japan Neuroprotective Drugs Sales and Growth Rate (2013-2018)

7.4 Korea Neuroprotective Drugs Sales and Growth Rate (2013-2018)

7.5 India Neuroprotective Drugs Sales and Growth Rate (2013-2018)

7.6 Southeast Asia Neuroprotective Drugs Sales and Growth Rate (2013-2018)

8 South America Neuroprotective Drugs by Countries

8.1 South America Neuroprotective Drugs Sales, Revenue and Market Share by Countries

8.1.1 South America Neuroprotective Drugs Sales and Market Share by Countries (2013-2018)

8.1.2 South America Neuroprotective Drugs Revenue and Market Share by Countries (2013-2018)

8.2 Brazil Neuroprotective Drugs Sales and Growth Rate (2013-2018)

8.3 Argentina Neuroprotective Drugs Sales and Growth Rate (2013-2018)

8.4 Colombia Neuroprotective Drugs Sales and Growth Rate (2013-2018)

9 Middle East and Africa Neuroprotective Drugs by Countries

9.1 Middle East and Africa Neuroprotective Drugs Sales, Revenue and Market Share by Countries

9.1.1 Middle East and Africa Neuroprotective Drugs Sales and Market Share by Countries (2013-2018)

9.1.2 Middle East and Africa Neuroprotective Drugs Revenue and Market Share by Countries (2013-2018)

9.2 Saudi Arabia Neuroprotective Drugs Sales and Growth Rate (2013-2018)

9.3 UAE Neuroprotective Drugs Sales and Growth Rate (2013-2018)

9.4 Egypt Neuroprotective Drugs Sales and Growth Rate (2013-2018)

9.5 Nigeria Neuroprotective Drugs Sales and Growth Rate (2013-2018)

9.6 South Africa Neuroprotective Drugs Sales and Growth Rate (2013-2018)

10 Global Neuroprotective Drugs Market Segment by Type

10.1 Global Neuroprotective Drugs Sales, Revenue and Market Share by Type (2013-2018)

10.1.1 Global Neuroprotective Drugs Sales and Market Share by Type (2013-2018)

10.1.2 Global Neuroprotective Drugs Revenue and Market Share by Type (2013-2018)

10.2 Cholinesterase inhibitors Sales Growth and Price

10.2.1 Global Cholinesterase inhibitors Sales Growth (2013-2018)

10.2.2 Global Cholinesterase inhibitors Price (2013-2018)

10.3 Anti-inflammatory Sales Growth and Price

10.3.1 Global Anti-inflammatory Sales Growth (2013-2018)

10.3.2 Global Anti-inflammatory Price (2013-2018)

10.4 Others Sales Growth and Price

10.4.1 Global Others Sales Growth (2013-2018)

10.4.2 Global Others Price (2013-2018)

11 Global Neuroprotective Drugs Market Segment by Application

11.1 Global Neuroprotective Drugs Sales Market Share by Application (2013-2018)

11.2 Alzheimer's disease Sales Growth (2013-2018)

11.3 Parkinson's disease Sales Growth (2013-2018)

11.4 Others Sales Growth (2013-2018)

12 Neuroprotective Drugs Market Forecast (2018-2023)

12.1 Global Neuroprotective Drugs Sales, Revenue and Growth Rate (2018-2023)

12.2 Neuroprotective Drugs Market Forecast by Regions (2018-2023)

12.2.1 North America Neuroprotective Drugs Market Forecast (2018-2023)

12.2.2 Europe Neuroprotective Drugs Market Forecast (2018-2023)

12.2.3 Asia-Pacific Neuroprotective Drugs Market Forecast (2018-2023)

12.2.4 South America Neuroprotective Drugs Market Forecast (2018-2023)

12.2.5 Middle East and Africa Neuroprotective Drugs Market Forecast (2018-2023)

12.3 Neuroprotective Drugs Market Forecast by Type (2018-2023)

12.3.1 Global Neuroprotective Drugs Sales Forecast by Type (2018-2023)

12.3.2 Global Neuroprotective Drugs Market Share Forecast by Type (2018-2023)

12.4 Neuroprotective Drugs Market Forecast by Application (2018-2023)

12.4.1 Global Neuroprotective Drugs Sales Forecast by Application (2018-2023)

12.4.2 Global Neuroprotective Drugs Market Share Forecast by Application (2018-2023)

13 Sales Channel, Distributors, Traders and Dealers

13.1 Sales Channel

13.1.1 Direct Marketing

13.1.2 Indirect Marketing

13.1.3 Marketing Channel Future Trend

13.2 Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendix

15.1 Methodology

15.2 Data Source

List of Tables and Figures

Figure Neuroprotective Drugs Picture

Table Product Specifications of Neuroprotective Drugs

Figure Global Sales Market Share of Neuroprotective Drugs by Types in 2017

Please fill the form below, to recieve the report sample


+1

Choose License Type

Reach Us

Email us at

sales@mrinsights.biz

Or call us on

US +1-201-465-4211

IND +91-906-779-0957

Why Choose Us

ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems

Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system

Global Outreach6 Major regions and 40+ countries level analysis accomplished

Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery